Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
加入 July 2010
1.2K 正在關注 145.5K 粉絲
In addition to weight loss, our investigational triple agonist reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent on the 9 mg dose in the TRIUMPH-1 study. Presented today at #ADA2026#. Read more:
顯示更多
